Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma (SeliSarc)
Status:
Recruiting
Trial end date:
2026-05-31
Target enrollment:
Participant gender:
Summary
Phase I-II, non-randomized, single-arm, open-label, multicenter, international clinical
trial.
Patients with advanced soft-tissue sarcoma (leiomyosarcoma or malignant peripheral nerve
sheath tumor) will receive selinexor in combination with gemcitabine.
Phase:
Phase 2
Details
Lead Sponsor:
Asociación Europea y Latinoamericana SELNET para la Investigación en Sarcomas